Q&A With John Yee From AstraZeneca: Developing New Diabetes Medications and Addressing Potential issues

One of the newest developments in the treatment of diabetes is the GLP-1 receptor agonist. With different forms intended for different populations it continues a longstanding pattern of bringing new medications into the pool of options for doctors to choose from.

One of the newest developments in the treatment of diabetes is the GLP-1 receptor agonist. With different forms intended for different populations it continues a longstanding pattern of bringing new medications into the pool of options for doctors to choose from.

John Yee, MD, MPH, from AstraZeneca discussed this new line of therapies and how they can help patients with their different processes during the American Diabetes Associations' 75h Annual Scientific Sessions in Boston. Yee said factors including how often the medication is used, associated costs, and safety concerns are all factored into the overall development process.